Clinical Trial: Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria

U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07524920) titled 'Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria' on March 27.

Brief Summary: This study aims to compare the efficacy and safety of two antibiotic combinations (Colistin + Meropenem) vs (Imipenem/cilastatin+ Tigecycline) in the treatment of adults with MDR gram-negative infections.

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: MDR Bacteria

Intervention: DRUG: "Imipenem/cilastatin" and "Tigecycline"

Imipenem/cilastatinis 500mg or 1gm every 6 to 8 hrs , Tigecycline 200 mg loading dose once followed by 100mg BID...